No Data
No Data
Chaoju Eye Care Arms Ink Five Tenancy Deals in Inner Mongolia
Chaoju Eye Care Holdings (HKG:2219) said subsidiaries Baotou City Chaoju Eye Hospital and Chaoju Medical Technology will lease three premises located in China's Inner Mongolia autonomous region from B
Several subsidiaries of Chaoju Ophthalmology (02219) signed separate lease agreements for 5 rental properties
Zhitong Finance App News, Chaoju Ophthalmology (02219) issued an announcement. On April 15, 2024, Baotou Hospital, a subsidiary of the company, signed a lease agreement I with Baotou Chaoju to lease property I for the period from April 15, 2024 to December 31, 2029. On April 15, 2024, Chaoju Medical, a subsidiary of the company, signed a lease agreement II with Baotou Chaoju to lease property II for the period from April 15, 2024 to December 31, 2029. On April 15, 2024, Chaoju Medical and Baotou Chaoju signed a lease agreement III to lease property III.
Chaoju Ophthalmology (02219.HK) obtained ORCHID ASIA VII GP, LIMITED increased its common stock holdings by 265,900, worth approximately HK$995,200
On April 15, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 15, ORCHID ASIA VII GP, LIMITED increased its share holdings of $Chaoju Ophthalmology (02219.HK) by $265,900 at an average price of HK$3,7547 per share on April 12, worth approximately HK$995,200. After the increase in holdings, ORCHID ASIA VII GP, LIMITED's latest shareholding was 77.9452 million shares, and the good position ratio increased from 10.98% to 11.02%. This transaction involves other related parties: OAV
China Post Securities: Endogenous growth is steady, and the Hong Kong stock healthcare services sector's valuation is highly attractive
Judging from the overall performance of medical service targets in Hong Kong stocks, with the exception of ICL's high revenue base in the early COVID-19 period, where dental revenue was affected by dental implant collection, most of the revenue from other medical service targets increased relatively well.
Chaoju Ophthalmology (2219.HK): Looking forward to steady revenue growth in 24 years
Incident: On March 26, 2024, the company issued an announcement. In 2023, it achieved operating income of 1369.5 million yuan, +38.3% year-on-year, and realized net profit before tax of 299.2 million yuan, +25.1% year-on-year.
Chaoju Ophthalmology (02219.HK): Strong mergers and acquisitions in basic consumer ophthalmology combine rapid expansion
Incident: On the evening of March 26, 2024, Chaoju Ophthalmology released its 2023 report. The company achieved main operating income of 1.37 billion yuan (+38.33%) and gross profit of 621 million yuan (+42.89%)
No Data